Aetna Updates Commercial Drug Lists

April 2018 ~

Effective July 1, Aetna will update its pharmacy plan drug lists. These changes will affect all Pharmacy Management drug lists, precertification, quantity limits and step-therapy programs.

These changes are as follows:

  • Granulocyte-Colony Stimulating Factor Products
    • Granix® (injection tbo-filgrastim)
    • Leukine® (injection sargramostim, GM-CSF)
    • Neulasta® (injection pegfilgrastim)
    • Neupogen® (injection filgrastim, G-CSF)
    • Zarxio® (injection filgrastim, G-CSF, biosimilar)
  • As of July 1, 2018, Zarxio® will be considered the least costly short-acting granulocyte colony-stimulating factor (G-CSF) product.
  • All G-CSFs will remain on the National Precertification List and require precertification.
  • Coverage for Neupogen® and Granix® will require a trial of Zarxio® and will also need to meet the clinical precertification criteria.
  • Neulasta® will not be affected by this change.

A list of these changes can be seen on Aetna’s Formularies & Pharmacy Clinical Policy Bulletins page. Note: for Aetna Standard Plan, these changes will be made available in May 2018.


Source(s): Aetna OfficeLink Updates All regions;